$KPTI SEC Filings

Filed On	Filing
22 Oct 2026	8-K: Other Events As previously disclosed in the Current Reports on Form 8-K filed by Karyopharm Therapeutics Inc. (the “Company”) on September 11, 2026 and October 14, 2026, the Company entered into a Forbearance Agreement and Limited Waiver to Indenture...
19 Oct 2026	Form 4: Abate Kristin, Chief Accounting Officer Sold 4,788 shares ($1.65K)
14 Oct 2026	8-K: Other Events As previously disclosed in the Current Report on Form 8-K filed by Karyopharm Therapeutics Inc. (the “Company”) on September 11, 2026, the Company entered into a Forbearance Agreement and Limited Waiver to Indentures, dated September 10,...
08 Oct 2026	SCHEDULE 13G/A
02 Oct 2026	Form 4: Abate Kristin, Chief Accounting Officer Sold 378 shares ($450)
25 Sep 2026	SCHEDULE 13G/A
25 Sep 2026	SCHEDULE 13G/A
18 Sep 2026	8-K: Material Modifications to Rights of Security Holders; Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year On September 17, 2026, the Pricing Committee of the Board of Directors of Karyopharm Therapeutics Inc., a Delaware corporation (the “Company”), acting pursuant to authority delegated to it by the Board of Directors on September 10, 2026 ...
11 Sep 2026	8-K: Entry into a Material Definitive Agreement; Triggering Events That Accelerate a Financial Obligation +2 more This Forbearance Agreement and Limited Waiver to Indentures, dated as of September 10, 2026 (this “Agreement”), is entered into by and among (i) Karyopharm Therapeutics Inc., a Delaware corporation (the “Company”) and each of the undersi...
04 Sep 2026	SCHEDULE 13G
02 Sep 2026	Form 4: Abate Kristin, Chief Accounting Officer Sold 19 shares ($38.4)
31 Aug 2026	8-K: Other Events
14 Aug 2026	SCHEDULE 13G/A
14 Aug 2026	SCHEDULE 13G/A
13 Aug 2026	10-Q
13 Aug 2026	8-K: Results of Operations and Financial Condition
12 Aug 2026	SCHEDULE 13G/A
11 Aug 2026	SCHEDULE 13G/A
31 Jul 2026	8-K: Other Events
30 Jul 2026	Form 4: Poulton Stuart, EVP, Chief Development Officer Sold 189 shares ($1.34K)

Comments